Steven Cohen Prometheus Biosciences, Inc. Transaction History

Point72 Asset Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$103.46 - $126.29 $20.6 Million - $25.2 Million	199,337 Added 15.74%	1,465,420 $157 Million
Q4 2022 Feb 14, 2023	BUY	$36.06 - $117.21 $24.3 Million - $78.9 Million	673,187 Added 113.54%	1,266,083 $139 Million
Q3 2022 Nov 14, 2022	SELL	$28.17 - $59.01 $21.8 Million - $45.6 Million	-773,530 Reduced 56.61%	592,896 $35 Million
Q2 2022 Aug 15, 2022	BUY	$22.39 - $38.94 $29.5 Million - $51.3 Million	1,316,426 Added 2632.85%	1,366,426 $38.6 Million
Q1 2022 May 16, 2022	SELL	$30.13 - $50.0 $2.55 Million - $4.23 Million	-84,537 Reduced 62.84%	50,000 $1.89 Million
Q4 2021 Feb 14, 2022	SELL	$22.28 - $39.54 $13.4 Million - $23.8 Million	-601,865 Reduced 81.73%	134,537 $5.32 Million
Q3 2021 Nov 15, 2021	SELL	$20.89 - $26.96 $578,653 - $746,792	-27,700 Reduced 3.63%	736,402 $17.5 Million
Q2 2021 Aug 16, 2021	SELL	$16.8 - $29.65 $603,086 - $1.06 Million	-35,898 Reduced 4.49%	764,102 $18.8 Million
Q1 2021 May 17, 2021	BUY	$16.51 - $25.29 $13.2 Million - $20.2 Million	800,000 New	800,000 $14.6 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.